Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr 27;22(9):4557.
doi: 10.3390/ijms22094557.

Immune-Mediated Drug-Induced Liver Injury: Immunogenetics and Experimental Models

Alessio Gerussi  1   2 , Ambra Natalini  3 , Fabrizio Antonangeli  3 , Clara Mancuso  1   2 , Elisa Agostinetto  4   5   6 , Donatella Barisani  1   2 , Francesca Di Rosa  3 , Raul Andrade  7 , Pietro Invernizzi  1   2
Affiliations
Review

Immune-Mediated Drug-Induced Liver Injury: Immunogenetics and Experimental Models

Alessio Gerussi et al. Int J Mol Sci. .

Abstract

Drug-induced liver injury (DILI) is a challenging clinical event in medicine, particularly because of its ability to present with a variety of phenotypes including that of autoimmune hepatitis or other immune mediated liver injuries. Limited diagnostic and therapeutic tools are available, mostly because its pathogenesis has remained poorly understood for decades. The recent scientific and technological advancements in genomics and immunology are paving the way for a better understanding of the molecular aspects of DILI. This review provides an updated overview of the genetic predisposition and immunological mechanisms behind the pathogenesis of DILI and presents the state-of-the-art experimental models to study DILI at the pre-clinical level.

Keywords: autoimmune hepatitis; autoimmunity; drug-induced liver injury; genetics; inflammation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
(A–D) Innate and adaptive immune responses in DILI.
See this image and copyright information in PMC

References

    1. Hoofnagle J.H., Björnsson E.S. Drug-Induced Liver Injury—Types and Phenotypes. N. Engl. J. Med. 2019;381:264–273. doi: 10.1056/NEJMra1816149. - DOI - PubMed
    1. Stephens C., Robles-Diaz M., Medina-Caliz I., Garcia-Cortes M., Ortega-Alonso A., Sanabria-Cabrera J., Gonzalez-Jimenez A., Alvarez-Alvarez I., Slim M., Jimenez-Perez M., et al. Comprehensive analysis and insights gained from long-term experience of the Spanish DILI registry. J. Hepatol. 2021 doi: 10.1016/j.jhep.2021.01.029. - DOI - PubMed
    1. Andrade R., Andrade R., Aithal G., Björnsson E., Kaplowitz N., Kullak-Ublick G., Larrey D., Karlsen T. EASL Clinical Practice Guidelines: Drug-induced liver injury. J. Hepatol. 2019 doi: 10.1016/j.jhep.2019.02.014. - DOI - PubMed
    1. Garcia-Cortes M., Robles-Diaz M., Stephens C., Ortega-Alonso A., Lucena M.I., Andrade R.J. Drug induced liver injury: An update. Arch. Toxicol. 2020;94:3381–3407. doi: 10.1007/s00204-020-02885-1. - DOI - PubMed
    1. Björnsson E., Talwalkar J., Treeprasertsuk S., Kamath P.S., Takahashi N., Sanderson S., Neuhauser M., Lindor K. Drug-induced autoimmune hepatitis: Clinical characteristics and prognosis. Hepatology. 2010;51:2040–2048. doi: 10.1002/hep.23588. - DOI - PubMed

MeSH terms